Pfizer Bet Hits Major Setback: Lung Cancer Drug Fails Trial, Triggering Market Jitters

Pfizer Bet Hits Major Setback: Lung Cancer Drug Fails Trial, Triggering Market Jitters​

Experimental Drug Failure Undermines $43 Billion Seagen Acquisition​

Pfizer Inc. has announced that one of its key experimental drugs failed to meet expectations in a critical advanced-stage lung cancer trial. The drug, sigvotatug vedotin, did not show a significant improvement in survival for patients whose cancers could not be treated surgically.

The setback significantly affects the future outlook for this medicine. Pfizer had acquired Seagen Inc. for $43 billion in late 2023, and the company was banking on sigvotatug vedotin becoming a leading drug of a new class. This class involves directed antibody-drug conjugates that deliver powerful cancer-killing compounds directly to tumors.

Pfizer shares saw a decline of about 1.5% during late trading after markets closed in New York following the news. The specific drug targets integrin beta-6, a protein present in roughly 90% of non-small cell lung cancers. Patients who have this characteristic often face a poor prognosis.

Investor Expectations and Clinical Trial Details​

The clinical trial focused on patients with advanced forms of lung cancer. Pfizer stated that the patients receiving sigvotatug vedotin did not live significantly longer compared to those treated with standard therapy involving docetaxel.

Barclays analysts had previously noted in May that investor expectations for the results were modest, largely because Pfizer had revised its study protocol. The company narrowed the focus solely onto overall survival rather than other potential endpoints.

Jeff Legos, Pfizer Chief Oncology Officer, expressed disappointment over the outcome in an interview. However, he stressed that this result is part of a larger and ongoing development program for both the drug and Pfizer’s ambitions within lung cancer treatment. He emphasized that "This isn't the end of the story."

Path Forward: Focus Shifts to Earlier Stages and Combinations​

Despite the disappointing results from the latest trial, Pfizer has signaled its continued commitment to the sigvotatug vedotin program. The company highlighted ongoing research efforts to mitigate the current setback.

A crucial development is a late-stage study currently evaluating sigvotatug vedotin in combination with Merck & Co.’s Keytruda. This combined approach is being tested as a first-line treatment for newly diagnosed patients.

Pfizer executives also shared data from previous studies that suggest the drug may be more effective when administered in earlier stages of cancer treatment. Furthermore, these past findings indicate potential benefit when used alongside immunotherapy.